文献速递肺外科

早期非小细胞肺癌:SBRT与肺叶切除术后复发比较

Recurrence After Stereotactic Body Radiation Therapy Versus Lobectomy for Non-Small Cell Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2020-04-27

单中心回顾性研究纳入554例临床T1-2N0非小细胞肺癌患者,肺叶切除389例、SBRT 165例,经2:1倾向评分匹配后比较132例SBRT与85例肺叶切除。SBRT与局部复发、区域淋巴结复发、总生存和无进展生存均更差相关,远处复发无差异。

要点

  • SBRT组局部复发风险显著高于肺叶切除(HR 6.80)。
  • SBRT组区域淋巴结复发风险更高(HR 2.58)。
  • SBRT组总生存和无进展生存均更差。

核心结论

  • 早期非小细胞肺癌肺叶切除的结局优于SBRT,包括局部区域控制。
  • 因选择偏倚需谨慎解读,强调需随机前瞻数据明确相对疗效。

研究设计与样本

  • 单中心回顾性队列研究,纳入2008至2018年临床T1-2N0非小细胞肺癌患者。
  • 共554例,肺叶切除389例,SBRT 165例(生物有效剂量≥100 Gy10)。
  • 采用Cox比例风险模型和最近邻倾向评分2:1匹配调整混杂。
  • 匹配后SBRT 132例,肺叶切除85例。

临床怎么用

  • 对可手术早期NSCLC,肺叶切除在局部区域控制和生存上可能优于SBRT。
  • SBRT选择需权衡局部复发风险,尤其区域淋巴结复发。
  • 需结合随机前瞻数据澄清两种模态的相对疗效。

局限性

  • 回顾性设计存在选择偏倚。
  • 单中心样本量有限。
  • 缺乏随机证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although lobectomy remains the standard of care for early-stage non-small cell lung cancer, several studies suggest equipoise between lobectomy and stereotactic body radiation therapy (SBRT). However randomized evidence is lacking. We compared outcomes of early-stage non-small cell lung cancer patients treated with lobectomy or SBRT. METHODS: We included clinical T1-2N0 non-small cell lung cancer treated with lobectomy or SBRT to a biologically effective dose of ≥100 Gy10. We used Cox proportional hazards and nearest-neighbor propensity score (2:1) matching to adjust for confounders. Kaplan-Meier curves were used to assess survival and recurrence. RESULTS: We identified 554 patients treated with lobectomy (n = 389) or SBRT (n = 165) at our institution between 2008 and 2018. After propensity score matching, there were 132 SBRT patients and 85 lobectomy patients. SBRT was associated with increased local recurrence (hazard ratio [HR], 6.80; 95% confidence interval [CI], 1.92-24.10; P = .003) and regional nodal recurrence (HR, 2.58; 95% CI, 1.17-5.68; P = .018), and with worse overall survival (HR, 2.00; 95% CI, 1.21-3.32; P = .007) and progression-free survival (HR, 2.34; 95% CI, 1.50-3.67; P < .001). There was no difference in distant recurrence (HR, 1.19; 95% CI, 0.57-2.52; P = .64). CONCLUSIONS: We found superior outcomes in patients with early-stage non-small cell lung cancer treated with lobectomy compared with SBRT, including locoregional control. These findings should be interpreted with caution because of selection bias but underscore the importance of robust randomized prospective data to clarify the relative efficacy of these modalities.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Sebastian NT, Merritt RE, Abdel-Rasoul M, et al. Recurrence After Stereotactic Body Radiation Therapy Versus Lobectomy for Non-Small Cell Lung Cancer. Ann Thorac Surg. 2020. PMID: 32353436. doi:10.1016/j.athoracsur.2020.03.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。